This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BXRX Baudax Bio (BXRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Baudax Bio Stock (NASDAQ:BXRX) 30 days 90 days 365 days Advanced Chart Get Baudax Bio alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.01▼$3.47Volume310,872 shsAverage Volume281,029 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. Read More Receive BXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BXRX Stock News HeadlinesBaudax Bio Announces Corporate UpdateOctober 18, 2023 | finance.yahoo.comBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug TagOctober 2, 2023 | msn.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 9 at 2:00 AM | Banyan Hill Publishing (Ad)Why Is Baudax Bio (BXRX) Stock Up 75% Today?September 28, 2023 | investorplace.comBaudax Bio Shares Double After Orphan Drug Designation for TI-168September 28, 2023 | marketwatch.comBaudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With InhibitorsSeptember 28, 2023 | markets.businessinsider.comHere's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowSeptember 18, 2023 | finance.yahoo.comBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceSeptember 7, 2023 | finance.yahoo.comSee More Headlines BXRX Stock Analysis - Frequently Asked Questions How were Baudax Bio's earnings last quarter? Baudax Bio, Inc. (NASDAQ:BXRX) announced its earnings results on Wednesday, August, 16th. The company reported ($1.49) EPS for the quarter, topping the consensus estimate of ($2.04) by $0.55. When did Baudax Bio's stock split? Baudax Bio's stock reverse split before market open on Wednesday, November 30th 2022.The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Baudax Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/16/2023Today9/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BXRX CIK1780097 Webwww.baudaxbio.com Phone484-395-2440Fax484-395-2471Employees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($9.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.79 million Net MarginsN/A Pretax Margin-18,950.64% Return on EquityN/A Return on Assets-175.11% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.27 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($14.93) per share Price / Book0.00Miscellaneous Outstanding Shares52,460,000Free Float52,408,000Market Cap$1.14 million OptionableNot Optionable Beta1.57 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BXRX) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baudax Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
